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Background Findings Discussion
Opioids are considered the standard of practice for 
intraoperative and postoperative pain management but yield 
unfavorable outcomes.6 The research evidence demonstrates 
reductions in post-operative opioid use following intraoperative 
administration of dexmedetomidine.1,3,4,5,6 Due to the 
prospective nature of literature surrounding dexmedetomidine, 
the rate of implementation remains largely unknown.
The aim of this retrospective, observational project was to 
identify the rate of adoption of intraoperative dexmedetomidine 
administration among adult surgical patients at Providence 
Sacred Heart Medical Center (PSHMC) from January 1, 2015 
to December 31, 2019. Accordingly, investigation into 
dexmedetomidine administration at PSHMC may shed light on 
this strategy aimed to minimize opioid exposure
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Methods
• Retrospective, observational evidence-based practice project.
• Approved by the PSHMC Clinical Innovation and Research 
Council and deemed exempt from human subject's research by 
Providence Health Care Institutional Review Board.
• Data extracted, de-identified and stored in HIPPA compliant 
Redcap project database.
• Included adults over the age of 18 years, undergoing surgical 
procedure  from January 1, 2015 to December 31, 2019. 
• Excluded pediatric patients less than 18 years of age, intranasal 
dexmedetomidine administration, patients undergoing 
outpatient procedures not admitted to the hospital, hospital 
length of stay less than 24 hours and greater than 14 days, and 
morphine equivalent dosing exceeding 200 milligrams.
• Univariate and bivariate analyses examined baseline group 
comparability, occurrence of intraoperative dexmedetomidine 
administration. 
• Multivariable analysis examined independent risk factors 
associated with receiving intraoperative dexmedetomidine.
Intraoperative dexmedetomidine is an effective evidenced-
based strategy to promote opioid sparing effect and reduce 24-
hour opioid consumption.1,4,5,6 Findings identified a 2.5% 
occurrence of intraoperative dexmedetomidine and 96.3% 
opioid occurrence in adult surgical patients at (PSHMC) from 
January 1, 2015 to December 31, 2019. The occurrence of 
dexmedetomidine administration is not a widespread practice 
used at PSHMC, but its utilization is increasing. History of 
backpain and intraoperative opioid administration were 
independently associated with decreased intraoperative 
dexmedetomidine use. ENT, maxillofacial and oral surgery 
were the greatest risk factors for intraoperative 
dexmedetomidine administration. History of home opioid 
treatment was also associated with increased intraoperative 
dexmedetomidine use. The research evidence demonstrates 
that intraoperative dexmedetomidine is a promising new 
avenue to reduce postoperative opioid use.3,4,5,6 The purpose 
of this retrospective, observational project serves as a 
foundation for additional examination to identify and report
interventions to reduce opioid administration and improve
quality initiatives surrounding multimodal analgesia. 
Table 1. Comparison of Baseline Demographics and Characteristics 
(N=26,990)
Figure 2. Intraoperative Dexmedetomidine Administration 
Annual Trends at PSHMC
ASA: American Society of Anesthesiology Physical Classification; Dex: dexmedetomidine; 
SD: standard deviation; IQR: interquartile range; LOS: Length of Stay; IR: Interventional 
Radiology
Figure 1. Percentage of Cases Receiving Intraoperative 
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Table 2. Independent Risk Factors on Intraoperative 
Dexmedetomidine Administration at PSHMC









Opioids (Y) Dexmedetomidine (Y)
Characteristics Values Count Percent
Dexmedetomidine 668 2.5%
Gender Female 13,605 50.4%
Males 13,385 49.6%




History Backpain 5,716 21.2%
Chronic Pain 1,823 6.8%
Opioid Treatment 226 0.8%
Opioid Administration 25,993 96.3%














Age (years) 62 16
BMI (kg/m2) 29.7 40
Median IQR
Case Duration (minutes) 166 111-276
Phase 1 Duration (minutes) 69 52-94
Length of Stay (minutes) 6,142 4,166-9,302
Variable OR CI P-Value
Back Pain 0.92 0.85-1.26 <0.001
ENT, Maxillofacial, or Oral Surgery 6.15 4.60-8.23 <0.001
Cardiothoracic or Cardiovascular 3.64 2.93-4.54 <0.001
Neurosurgery 3.22 2.55-4.07 <0.001
Opioid Treatment 2.80 1.53-5.14 <0.001
Opioid Administration 0.54 0.36-0.81 <0.001
24-Hour Morphine Equivalent Dosing 1.00 1.00-1.00 0.035
